Such appears to be the casewith the opportunity that presented itself while we were exploring the mode ofaction of a novel chemopreventive agent, nitric oxide-donating aspirin (NO-ASA),and its relationship to peroxisome proliferator-activated receptor δ (PPARδ).Here, we discuss our findings, and to provide an appropriate perspective, wesummarize relevant aspects of the pharmacology of nitric oxide-donating nonsteroidalanti-inflammatory drugs (NO-NSAIDs), PPARδ cancer biology, and the relationshipbetween the two. The gene discussed is PPARD; the disease is cancer.